Appendix 4E and Preliminary Unaudited Financial Report
Filed with ASX · · 12 pages · English
Earlier from Argent Biopharma
- JV to be established for registration of ArtemiC in Russia
- COVID-19 Interim Trial Results Meet All Primary Objectives
- UK distribution agreement signed for MGC Pharma medicines
- Study confirms effectiveness of ArtemiC on human immune cell
- Trading halt
Later from Argent Biopharma
- $15M finance facility to fund revenue growth for key markets
- Mxc well positioned for tga down-schedule of cbd products
- Mxc welcomes new FCA guidance for cannabis sector in the UK
- Update on ArtemiC phase II trial on COVID-19 patients
- MGC pharma launches CannEpil app
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma